Which of the following drug is not used in MDB under RNTCP
Regimen for MDR-TB This regimen comprises of 6 drugs Kanamycin, Levofloxacin, Ethionamide, Pyrazinamide, Ethambutol and Cycloserine during 6-9 months of the intensive phase and 4 drugs-Levovfloxacin, Ethionamide, Ethambutol and Cycloserine during the 18 months of the continuation phase. RNTCP regimen for MDR-TB : 6 (9) Km Lvx Eto Cs Z E/ 18 Lvx Eto Cs E* (Reserve/substitute drugs : PAS, Mfx, Cm) Special adjustments to the standard regimen for MDR-TB are as follows: In case of intolerance to Kanamycin, then Capreomycin (or PAS if injectable agent not feasible) is the available substitute drug. - In case of intolerance leading to discontinuation of other oral second-line drug, p-aminosalicylic acid (PAS) is the available substitute drug. - Baseline Kanamycin mono-resistance should lead to substitution of Kanamycin with Capreomycin. - Baseline Ofloxacin mono-resistance should lead to substitution of Levofloxacin with the combination of Moxifloxacin and PAS. - Baseline Ofloxacin and Kanamycin resistance (i.e. XDR-TB) should lead to declaration of outcome, referral to DR-TB Centre for pre-treatment evaluation for regimen for XDR-TB. Ref : Park 23rd edition Pgno : 191
Levofloxacin
Cycloserine
PAS
Ethionamide
Communicable diseases